A new analysis of randomized controlled trials of the widely used new generation cancer drug bevacizumab (marketed by Roche and Genentech as Avastin) found it was linked to an increased risk of deep vein blood clots or venous thromboembolism in the legs or lungs compared with treatments that did not use it.